- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Rehabilitation
- Neuromodulation
Central Data Repository
Explore the Central Data Repository: Use the filters and keyword search box on the left to find relevant studies. As you refine your search, the map and study list will automatically update to reflect your selections. Selecting a study from the list will provide detailed information about the specific study in question. A full legend can be found here
{content}
Study list
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Influenza A
- Influenza B
- Pharmacological intervention
- Immunomodulator
- PRS CK STORM
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Oxygen therapy
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- Respiratory syncytial virus
- Pharmacological intervention
- Vaccination
- Adults (18-64 years)
- General population
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Non pharmacological intervention
- Essential Oils
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Apo-Si-K170A-C76
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Monkeypox virus
- Pharmacological intervention
- Antivirals
- Tecovirimat
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Rehabilitation
- Cardiac coherence
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Non pharmacological intervention
- Rehabilitation
- Education
- Adults (18-64 years)
- General population
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Rehabilitation
- Neurostimulation
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Children (1-11 years)
- Outpatient clinic
- Arbovirus
- Dengue virus
- Vector-borne disease
- Blood sample
- Pharmacological intervention
- Vaccination
- Qdenga
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Rehabilitation
- Vimida
- Adults (18-64 years)
- Community
- Primary care
- SARS-CoV-2
- Influenza virus
- Influenza A(H5N1) virus
- Pharmacological intervention
- Nitric Oxide Nasal Spray
- Adults (18-64 years)
- General population
- Outpatient clinic
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Aterixen
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Rehabilitation
- Stimulation
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Pharmacological intervention
- Vaccination
- Infants (<1 year)
- Fragile population
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Pharmacological intervention
- Vaccination
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Intensive care unit
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- Primary care
- SARS-CoV-2
- Influenza virus
- Influenza-like illness/Acute respiratory infection
- Pharmacological intervention
- Antivirals
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- Respiratory syncytial virus
- Pharmacological intervention
- Vaccination
- Arexvy
- Adults (18-64 years)
- Fragile population
- People at high risk of STIs
- Immunocompromised host
- PrEP users
- People living with HIV
- Outpatient clinic
- Non-hospital health centre
- STD/STI clinic
- Monkeypox virus
- Adults (18-64 years)
- General population
- Hospital
- Outpatient clinic
- Monkeypox virus
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Outpatient clinic
- Respiratory syncytial virus
- Bordetella pertussis
- Blood sample
- Nasopharyngeal swab